Exhibit 32.1
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350,
AS
ADOPTED PURSUANT TO
SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
In
connection with the Quarterly Report on Form 10-Q of Monopar
Therapeutics Inc. (the Company) for the three and six months ended
June 30, 2020, as filed with the Securities and Exchange Commission
on the date hereof (the Report), we, Chandler D. Robinson, and Kim
R. Tsuchimoto, hereby certify, pursuant to 18 U.S.C. §1350, as
adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002,
that:
(1)
the Report
fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and
(2)
the
information contained in the Report fairly presents, in all
material respects, the financial condition and results of
operations of the Company.
/s/ Chandler D.
Robinson
Chandler D.
Robinson
Chief
Executive Officer
August
6, 2020
/s/ Kim
R. Tsuchimoto
Kim R.
Tsuchimoto
Chief
Financial Officer
August
6, 2020
This
certification accompanies the Form 10-Q to which it relates, is not
deemed filed with the Securities and Exchange Commission and is not
to be incorporated by reference into any filing of Monopar
Therapeutics Inc. under the Securities Act of 1933, as amended, or
the Securities Exchange Act of 1934, as amended (whether made
before or after the date of the Form 10-Q), irrespective of any
general incorporation language contained in such
filing.